ARQT - Company ID 0001787306
The table below shows Arcutis Biotherapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $105.40M | $99.22M | $81.50M | $65.85M | $44.76M | $30.86M |
| Cost of revenue | $9.78M | $8.69M | $7.49M | $8.83M | $5.50M | $3.46M |
| Gross profit | - | - | - | - | - | - |
| R&D | $30.63M | $19.60M | $19.45M | $17.54M | $19.50M | $19.30M |
Arcutis Biotherapeutics, Inc. reported annual revenue of $376.07M for fiscal year 2025. That is up 91.3% from $196.54M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $74.08M |
| $62.40M |
| $69.17M |
| $64.00M |
| $58.82M |
| $58.17M |
| Operating income | -$9.09M | $8.53M | -$14.61M | -$24.53M | -$39.07M | -$50.08M |
| Income tax | $93.00K | $80.00K | $342.00K | $279.00K | $0.00 | $0.00 |
| Net income | -$11.29M | $7.41M | -$15.89M | -$25.06M | -$41.54M | -$52.33M |
| EPS (diluted) | -$0.09 | $0.06 | -$0.13 | -$0.20 | -$0.33 | -$0.42 |